Igel Talia F, Krasnokutsky Svetlana, Pillinger Michael H
The Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, NY, USA; The School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia.
The Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, NY, USA.
F1000Res. 2017 Mar 10;6:247. doi: 10.12688/f1000research.9402.1. eCollection 2017.
Gout is the most common crystal arthropathy and the leading cause of inflammatory arthritis. It is associated with functional impairment and, for many, a diminished health-related quality of life. Numerous studies have demonstrated the impact of gout and its associated conditions on patient morbidity and mortality. Unfortunately, gout remains under-diagnosed and under-treated in the general community. Despite major advances in treatment strategies, as many as 90% of patients with gout are poorly controlled or improperly managed and their hyperuricemia and recurrent flares continue. The introduction of novel urate-lowering therapies, new imaging modalities, and a deeper understanding of the pathogenesis of gout raise the possibility of better gout care and improved patient outcomes. Here, we spotlight recent advances in the diagnosis and management of gout and discuss novel therapeutics in gout treatment.
痛风是最常见的晶体性关节病,也是炎症性关节炎的主要病因。它与功能障碍相关,对许多人来说,还会导致健康相关生活质量下降。大量研究已证明痛风及其相关病症对患者发病率和死亡率的影响。不幸的是,痛风在普通人群中仍未得到充分诊断和治疗。尽管治疗策略取得了重大进展,但多达90%的痛风患者控制不佳或管理不当,其高尿酸血症和反复发作仍在继续。新型降尿酸疗法、新的成像方式的引入,以及对痛风发病机制更深入的了解,增加了改善痛风治疗和提高患者治疗效果的可能性。在此,我们重点介绍痛风诊断和管理方面的最新进展,并讨论痛风治疗中的新型疗法。